Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

Official Title

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer


This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people or what dose should be used. Therefore, the main purpose of this study is to assess the safety (side effects) of EPI-7386 and to find a dose that can be given without unacceptable side effects. There are other important things that will be evaluated during the study: - How the amount of EPI-7386 in the blood changes over time. - The effect of EPI-7386 on prostate cancer. - The effect of EPI-7386 on certain substances in the body. - The possibility that EPI-7386 can interact with other drugs.

Trial Description

Primary Outcome:

  • The primary safety variable for Part 1a of the study is the incidence of protocol-defined DLT during the DLT assessment period (first 28 days of dosing).
  • The primary efficacy variable for Part 1b of the study is the proportion of patients with a decline from baseline in PSA blood concentrations of ≥50% at any time point during daily dosing with EPI-7386.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society